Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,377,614
  • Shares Outstanding, K 51,394
  • Annual Sales, $ 336,890 K
  • Annual Income, $ -87,940 K
  • EBIT $ -42 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.42
  • Price/Sales 9.87
  • Price/Cash Flow N/A
  • Price/Book 11.12

Options Overview Details

View History
  • Implied Volatility 47.78% (+0.54%)
  • Historical Volatility 32.57%
  • IV Percentile 37%
  • IV Rank 34.92%
  • IV High 77.45% on 12/23/24
  • IV Low 31.86% on 08/21/25
  • Expected Move (DTE 7) 4.08 (6.28%)
  • Put/Call Vol Ratio 0.89
  • Today's Volume 17
  • Volume Avg (30-Day) 85
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 3,405
  • Open Int (30-Day) 2,481
  • Expected Range 60.92 to 69.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 6
  • High Estimate 0.01
  • Low Estimate -0.18
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +87.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.48 +2.39%
on 12/08/25
74.96 -13.29%
on 12/01/25
-5.78 (-8.17%)
since 11/12/25
3-Month
63.48 +2.39%
on 12/08/25
78.54 -17.24%
on 10/09/25
-9.31 (-12.53%)
since 09/12/25
52-Week
36.88 +76.25%
on 04/09/25
78.54 -17.24%
on 10/09/25
+22.72 (+53.74%)
since 12/12/24

Most Recent Stories

More News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...

MIRM : 65.00 (-1.10%)
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations -Anticipated to be highly synergistic with...

MIRM : 65.00 (-1.10%)
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027

MIRM : 65.00 (-1.10%)
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan...

MIRM : 65.00 (-1.10%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...

MIRM : 65.00 (-1.10%)
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®

New data reinforce Mirum’s commitment to advancing therapies and improving the lives of patients across diverse rare liver diseases.

MIRM : 65.00 (-1.10%)
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

- Third quarter 2025 total revenue of $133 million - 2025 revenue guidance updated to $500 to $510 million - Phase 2b VISTAS topline data expected second quarter of 2026 - Conference...

MIRM : 65.00 (-1.10%)
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan...

MIRM : 65.00 (-1.10%)
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report third quarter 2025 financial results on November 4, 2025. Mirum will also host a conference call to discuss the third quarter...

MIRM : 65.00 (-1.10%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on October 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...

MIRM : 65.00 (-1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 69.24
2nd Resistance Point 68.01
1st Resistance Point 66.86
Last Price 65.00
1st Support Level 64.48
2nd Support Level 63.25
3rd Support Level 62.10

See More

52-Week High 78.54
Last Price 65.00
Fibonacci 61.8% 62.63
Fibonacci 50% 57.71
Fibonacci 38.2% 52.80
52-Week Low 36.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar